Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer Decreases Distant Recurrence and Could Eradicate Local Recurrence

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of Surgical Oncology

• Publication date

  2011-01-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-010-1506-1PMID 21207164
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Practice parameters for the management of rectal cancer (revised).

  2013cited by this paper
• Neoadjuvant Therapy for Rectal Cancer: The Impact of Longer Interval Between Chemoradiation and Surgery

  2011cited by this paper
• Revised TN categorization for colon cancer based on national survival outcomes data.

  2010cited by this paper
• Downstaging Without Complete Pathologic Response After Neoadjuvant Treatment Improves Cancer Outcomes for cIII but not cII Rectal Cancers

  2010cited by this paper
• Downstaging After Chemoradiotherapy for Locally Advanced Rectal Cancer: Is There More (Tumor) Than Meets the Eye?

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• Locally Recurrent Rectal Cancer: Prognostic Factors and Long-Term Outcomes of Multimodal Therapy

  2010cited by this paper
• Genetic and molecular diversity of colon cancer hepatic metastases.

  2009cited by this paper
• Locally Recurrent Rectal Cancer: Prognostic Factors and Long-Term Outcomes of Multimodal Therapy

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Neoadjuvant Chemoradiation for Rectal Cancer Reduces Lymph Node Harvest in Proctectomy Specimens

  2009cited by this paper
• Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer

  2009cited by this paper
• In Reply: Local Excision as an Optional Tool to Individualize Treatment of Rectal Cancer

  2008cited by this paper
• An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease–Free Survival in Patients with Locally Advanced Rectal Cancer

  2008cited by this paper
• Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

  2008cited by this paper
• Neoadjuvant Chemoradiation and Local Excision for T2-3 Rectal Cancer

  2008cited by this paper
• Absence of Lymph Nodes in the Resected Specimen After Radical Surgery for Distal Rectal Cancer and Neoadjuvant Chemoradiation Therapy: What does it Mean?

  2008cited by this paper
• Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

  2008cited by this paper
• Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer.

  2007cited by this paper
• Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

  2007cited by this paper
• Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.

  2007cited by this paper
• The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma

  2007cited by this paper
• Chemotherapy with Preoperative Radiotherapy in Rectal Cancer

  2007cited by this paper
• Commented Summaries

  2006cited by this paper
• Chemotherapy with preoperative radiotherapy in rectal cancer.

  2006cited by this paper
• A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography

  2006cited by this paper
• Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

  2006cited by this paper
• Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery.

  2006cited by this paper
• Lymph node evaluation in colorectal cancer patients: a population-based study.

  2005cited by this paper
• Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer

  2005cited by this paper
• Long‐term results in patients with T2–3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery

  2005cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Practice Parameters for the Management of Rectal Cancer (Revised)

  2005cited by this paper
• Preoperative versus postoperative chemoradiotherapy for rectal cancer.

  2004cited by this paper
• Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy.

  2004cited by this paper
• Does Rectal Wall Tumor Eradication With Preoperative Chemoradiation Permit a Change in the Operative Strategy?

  2004cited by this paper
• Complete Pathologic Response Following Preoperative Chemoradiation Therapy for Middle to Lower Rectal Cancer Is Not a Prognostic Factor for a Better Outcome

  2004cited by this paper
• Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-term Results

  2004cited by this paper
• Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial

  2004cited by this paper
• Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck

  2004cited by this paper
• Curative Potential of Multimodality Therapy for Locally Recurrent Rectal Cancer

  2003cited by this paper
• Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.

  2003cited by this paper
• A Pathologic Complete Response to Preoperative Chemoradiation Is Associated With Lower Local Recurrence and Improved Survival in Rectal Cancer Patients Treated by Mesorectal Excision

  2003cited by this paper
• Multi‐modality approach in curative local treatment of early rectal carcinomas

  2003cited by this paper
• Combined-Modality Therapy in Locally Advanced Primary Rectal Cancer

  2003cited by this paper
• Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy.

  2002cited by this paper
• Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Treatment of colon and rectal cancer.

  2002cited by this paper
• Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers

  2002cited by this paper
• Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls.

  2002cited by this paper
• A National Strategic Change in Treatment Policy for Rectal Cancer—Implementation of Total Mesorectal Excision as Routine Treatment in Norway. A National Audit

  2002cited by this paper
• Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients.

  2002cited by this paper
• Local Excision of T2 and T3 Rectal Cancers After Downstaging Chemoradiation

  2001cited by this paper
• Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 to T4 rectal cancer

  2001cited by this paper
• Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival

  2001cited by this paper
• Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer.

  2001cited by this paper
• Treatment of colon and rectal cancer.

  2000cited by this paper
• Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial.

  2000cited by this paper
• Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer.

  1999cited by this paper
• Total mesorectal excision is not necessary for cancers of the upper rectum.

  1998cited by this paper
• [Introduction of a new surgical technique in rectal cancer].

  1998cited by this paper
• Innføring av en ny operasjonsmetode for rectumcancer

  1998cited by this paper
• Mesorectal excision for rectal cancer: a view from Europe.

  1998cited by this paper
• Effect of the introduction of total mesorectal excision for the treatment of rectal cancer

  1998cited by this paper
• Long‐term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer

  1997cited by this paper
• Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer

  1997cited by this paper
• Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.

  1997cited by this paper
• Conservative Surgery for Low Rectal Carcinoma After High‐Dose Radiation Functional and Oncologic Results

  1995cited by this paper
• The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

  1993cited by this paper
• Effective surgical adjuvant therapy for high-risk rectal carcinoma.

  1991cited by this paper
• Effective surgical adjuvant therapy for high-risk rectal carcinoma.

  1991cited by this paper
• Adjuvant therapy for patients with colon and rectal cancer. National Institutes of Health.

  1990cited by this paper
• NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.

  1990cited by this paper
• Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference.

  1990cited by this paper
• Applied Logistic Regression, Second Edition

  1989cited by this paper
• Recurrence and survival after total mesorectal excision for rectal cancer.

  1986cited by this paper
• Local recurrence after low anterior resection using the staple gun

  1982cited by this paper
• Local recurrences after sphincter‐saving excisions for carcinoma of the rectum and rectosigmoid

  1951cited by this paper

• Short-Term Outcomes of Laparoscopic Colorectal Cancer Surgery at a Tertiary Care Hospital: A Single-Surgeon Experience

  2026cites this paper
• Why Is There a Demand for Organ-Sparing Approaches in the Era of TNT and TME?

  2025cites this paper
• Total Neoadjuvant Therapy for Rectal Cancer: Why Japan Says “Not Yet”

  2025cites this paper
• The Role of Pre-Treatment Inflammatory Biomarkers in Predicting Tumor Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer

  2025cites this paper
• Prognosis and influencing factors of patients with different lymph node statuses after pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer

  2025cites this paper
• Conditional Survival in Patients with Locally Advanced Rectal Cancer and Pathologic Complete Response: Results from an Observational Retrospective Multicenter Long-Term Follow-Up Study

  2025cites this paper
• Optimal timing of surgery after neoadjuvant chemoradiotherapy in rectal cancer: A retrospective analysis.

  2025cites this paper
• Editorial: “Pathologic Complete Response, Total Neoadjuvant Therapy, and the Survival Paradox in Locally Advanced Rectal Cancer,” by Goffredo et al. Without Constancy There is Neither Love, Friendship, Nor Virtue in the World

  2024cites this paper
• Impact of adjuvant chemotherapy on survival after pathological complete response in rectal cancer: a meta-analysis of 31,558 patients

  2024cites this paper
• Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.

  2024cites this paper
• Value of perfusion parameters from golden-angle radial sparse parallel dynamic contrast-enhanced magnetic resonance imaging in predicting pathological complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer

  2024cites this paper
• Prolonged interval to surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A meta-analysis of randomized controlled trials.

  2024cites this paper
• Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Predicting Complete Pathological Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

  2024cites this paper
• Significant Pathologic Response Following Neoadjuvant Therapy and Curative Resection in Patients With Rectal Cancer: Surgical and Oncological Outcomes From a Retrospective Cohort Study

  2024cites this paper
• Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence.

  2024cites this paper
• Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review

  2023cites this paper
• Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer

  2023cites this paper
• Adverse impact of tumor deposits in lymph node negative rectal cancer — a national cohort study

  2023cites this paper
• Determining the optimal radiation‐surgery interval (RSI) for oncologic proctectomy following radiotherapy for rectal adenocarcinoma

  2023cites this paper
• Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial

  2023cites this paper
• Preoperative Intensification Treatment in Patients with Rectal Adenocarcinoma - A Standardization of Clinical Practice

  2023cites this paper
• A multi-class classification algorithm based on hematoxylin-eosin staining for neoadjuvant therapy in rectal cancer: a retrospective study

  2023cites this paper
• Evaluation of the role of inflammatory blood markers in predicting the pathological response after neoadjuvant chemoradiation in patients with locally advanced rectal cancer

  2023cites this paper
• "Long-term oncologic outcomes and risk factors for distant recurrence after pathologic complete response following neoadjuvant treatment for locally advanced rectal cancer. A nationwide, multicentre study".

  2023cites this paper
• Radiological Biomarkers in MRI directed Rectal Cancer Radiotherapy Volume Delineation

  2023cites this paper
• Analysis of Survival in Complete Pathological Response after Long-Course Chemoradiotherapy in Patients with Advanced Rectal Cancer

  2023cites this paper
• Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

  2022cites this paper
• Watch-and-Wait policy versus robotic surgery for locally advanced rectal cancer: A cost-effectiveness study (RECCOSTE).

  2022cites this paper
• Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis

  2022cites this paper
• Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer

  2022cites this paper
• A multicentre cohort study assessing the utility of routine blood tests as adjuncts to identify complete responders in rectal cancer following neoadjuvant chemoradiotherapy

  2022cites this paper
• Impact of preoperative chemoradiation with higher dose intensity modulated radiotherapy on pathological complete response for locally advanced rectal cancer: a systematic review

  2022cites this paper
• Mechanisms of microRNA action in rectal cancer radiotherapy

  2022cites this paper
• T‐stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics

  2022cites this paper
• Pathologic complete response after neoadjuvant chemotherapy/(re)chemoradiation for pelvic relapse of rectal cancer undergoing complex pelvic surgery: more frequent than expected?

  2022cites this paper
• Histopathological, Radiological, and Demographic Factors Predicting the Response to Neoadjuvant Therapy for Rectal Cancer

  2021cites this paper
• Prognostic factors in patients with complete response of the tumour (ypT0) after neoadjuvant chemoradiotherapy and radical resection of rectal cancer

  2021cites this paper
• When Should We Expect Curative Results of Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients?

  2021cites this paper
• Current evidence regarding the role of adjuvant chemotherapy in rectal cancer patients with pathologic complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis

  2021cites this paper
• Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer

  2021cites this paper
• Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?

  2021cites this paper
• Can histologic features predict neoadjuvant therapy response in rectal adenocarcinoma?

  2021cites this paper
• DELINEATING THE ROLE OF FATTY ACID METABOLISM TO IMPROVE THERAPEUTIC STRATEGIES FOR COLORECTAL CANCER

  2021cites this paper
• Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data

  2021cites this paper
• Biomarkers in Locally Advanced Rectal Cancer: A Review.

  2021cites this paper
• Poor nutrition and sarcopenia are related to systemic inflammatory response in patients with rectal cancer undergoing preoperative chemoradiotherapy

  2021cites this paper
• Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.

  2021cites this paper
• Anastomotic leak risk in complete responders to neoadjuvant therapy for rectal cancer: a systematic review

  2021cites this paper
• Predictive factors for tumour response after the neoadjuvant-treatment of rectal adenocarcinoma

  2020cites this paper
• Parameters for Predicting Tumour Response Following Neoadjuvant Chemoradiotherapy for Patients with Rectal Cancer.

  2020cites this paper
• Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single‐institution study with propensity score‐matched comparative analysis

  2020cites this paper
• Low rectal cancer treatment strategies: a cohort study assessing watch and wait

  2020cites this paper
• Predictive factors of complete pathological response in patients with locally advanced rectal cancer

  2020cites this paper
• A pathological complete response after neoadjuvant triplet chemotherapy for locally advanced transverse colon cancer

  2020cites this paper
• Prognosis and risk factors for the development of pulmonary metastases after preoperative chemoradiotherapy and radical resection in patients with locally advanced rectal cancer.

  2020cites this paper
• Oncologic effects of adjuvant chemotherapy in patients with ypT0–2N0 rectal cancer after neoadjuvant chemoradiotherapy and curative surgery: a meta-analysis

  2020cites this paper
• Ten‐year survival after pathologic complete response in rectal adenocarcinoma

  2020influential citation
• Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Tratamiento Multimodal del Cáncer de Recto, Visión del Oncólogo

  2020cites this paper
• Predictors for complete pathological response for stage II and III rectal cancer following neoadjuvant therapy - A systematic review and meta-analysis.

  2020cites this paper
• Local Therapy Options for Recurrent Rectal and Anal Cancer: Current Strategies and New Directions

  2019cites this paper
• Therapie des Rektumkarzinoms — ein Update

  2019cites this paper
• Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

  2019cites this paper
• ect of adding mFOLFOX 6 after neoadjuvant chemoradiation in locally advanced rectal cancer : a multicentre , phase 2 trial

  2019cites this paper
• The relationship between mesorectal grading and oncological outcome in rectal adenocarcinoma

  2019cites this paper
• Using Diffuse Reflectance Spectroscopy to Distinguish Tumor Tissue From Fibrosis in Rectal Cancer Patients as a Guide to Surgery.

  2019cites this paper
• Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.

  2019cites this paper
• Circulating biomarkers for response prediction of rectal cancer to neoadjuvant chemoradiotherapy.

  2019cites this paper
• Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer

  2019influential citation
• Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.

  2019cites this paper
• Rectal Cancer: Neoadjuvant Therapy

  2019cites this paper
• Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.

  2019cites this paper
• Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation

  2019cites this paper
• The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies

  2019cites this paper
• The treatment of early rectal cancer in the era of adjuvant and neo-adjuvant therapy

  2018cites this paper
• Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy?

  2018cites this paper
• Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer

  2018cites this paper
• Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection

  2018cites this paper
• Preliminary results of a cohort study of induction chemotherapy‐based treatment for locally recurrent rectal cancer

  2018cites this paper
• Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.

  2018cites this paper
• An update on the use of Raman spectroscopy in molecular cancer diagnostics: current challenges and further prospects

  2018cites this paper
• SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1α

  2018cites this paper
• Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

  2018cites this paper
• Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer

  2018cites this paper
• Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer

  2018cites this paper
• Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

  2018cites this paper
• OCT4 Potentiates Radio-Resistance and Migration Activity of Rectal Cancer Cells by Improving Epithelial-Mesenchymal Transition in a ZEB1 Dependent Manner

  2018cites this paper
• Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer

  2018cites this paper
• Quality of Life After Multidisciplinary Management of Rectal Cancer

  2018cites this paper
• Maximizing Neoadjuvant Treatment Response and Watch and Wait

  2018cites this paper
• Therapie des Rektumkarzinoms — ein Update

  2018cites this paper
• Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta‐analysis

  2018cites this paper
• Immune markers to predict response to neoadjuvant chemoradiotherapy and identifying methods to incorporate immunotherapy in locally advanced rectal cancer

  2018cites this paper
• Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer

  2017cites this paper
• One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer

  2017cites this paper
• Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer

  2017cites this paper
• Outcomes of Neoadjuvant Radiochemotherapy of Locally Advanced Rectal Adenocarcinoma: Results of 8 Year Experience in Iran Cancer Institute

  2017cites this paper
• Current Views on the Interval Between Neoadjuvant Chemoradiation and Surgery for Rectal Cancer

  2017cites this paper
• Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

  2017cites this paper